Wijkstrom Joakim's Form 4 filing
Vanda Pharmaceuticals Inc. (VNDA) · filed Mar 6, 2024
- Accession no.
- 0000950170-24-027259
- Filed
- Mar 6, 2024
- Trade date
- Mar 4-5, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $71.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Wijkstrom JoakimCIK 0001785888 | Officer (SVP, Chief Marketing Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 4, 2024 | Common Stock | SSaleDisposed | −7,498 | $4.41 | −$33,066.18 | 139,018 | Direct | |
| Mar 5, 2024 | Common Stock | SSaleDisposed | −9,229 | $4.21 | −$38,854.09 | 129,789 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.